#ESHLYMPHOID2021: UPDATED PROGRAMME NOW AVAILABLE!

August 30, 2021

6th ESH Translational Research Conference
LYMPHOID MALIGNANCIES

Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt

October 14-17, 2021 - E-Conference
FREE REGISTRATION

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

TIMING OF THE SCIENTIFIC PROGRAMME:
Participants will be joining us from all over the world and from different time zones. To make sure that everyone has access to the full scientific programme at a convenient hour, registration will allow participants to join both the LIVE PROGRAMME (October 14-17, 2021) and the PROGRAMME ON DEMAND (October 4 - November 17, 2021).

SCIENTIFIC TOPICS:

– B-cell development and lymphomagenesis
– Genetics of malignant lymphomas and clonal evolution
– Epigenetics in malignant lymphomas
– Deregulated proteome and metabolome
– Single cell analyses, circulating tumor DNA, MRD
– Oncogenic signaling pathways
– Utilizing oncogenic signaling therapeutically
– Immunologic approaches in the treatment of lymphomas

ABOUT THE PROGRAMME:
This leading-edge translational research conference will address the rapidly evolving field of lymphoid malignancies, including T- and B-cell lymphomas, and chronic lymphocytic leukaemia (CLL), from molecular pathogenesis to state-of-the-art treatment and future perspectives.

The goals of this conference are to:
– foster scientific exchange between laboratory scientists and clinicians working on lymphoid malignancies worldwide
– foster scientific cross-fertilization between researchers and clinicians working on different diseases with partially overlapping pathogenic mechanisms such as the B cell receptor signaling, alterations of the DNA damage response, or the increasingly important dialogue of lymphoid tumour cells with their microenvironment
– provide opportunities for leading-edge education and international networking to basic and clinical scientists, including those still in-training.

A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of Lymphoid Malignancies.

Learning objectives:
Improved understanding of :
– current developments in the field of molecular pathogenesis of indolent and aggressive B-cell lymphoma including CLL
– current developments in the field of the molecular pathogenesis of T-cell lymphoma
– prognostic and predictive markers and their impact in specific clinical situations
– current treatments and future therapeutic perspectives.

MORE INFORMATION

With the support of*: